$XTALPI(02228.HK)In February 2025, we signed a strategic cooperation agreement worth tens of millions of RMB with South Korea's JW Pharmaceutical. Jingtai Technology will deploy a series of high-throughput automated synthesis workstations, AI reaction condition optimization systems, and intelligent analysis platforms for JW to meet its complex R&D needs in automated drug candidate molecule screening, synthesis, and process optimization. This is not only the first time that Jingtai Technology's automated laboratory solutions have been purchased by an overseas pharmaceutical client, but also an important practice in the intelligent upgrade of drug R&D in Asia.

In December, the project reached a key milestone: JW's intelligent laboratory for drug discovery and process optimization was successfully delivered to the client site and accepted. These landmark achievements have paved a replicable path for the transformation of traditional pharmaceutical R&D towards an 'unmanned, data-driven' model.